Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Tempest Therapeutics, Inc.(TPST US)

$0.51-0.012.16%Ext:$0.64+0.1325.76%(Market Closed · 00:00:02 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings
CategorizedChronologicalBy Owner

Financials & Metrics

FinancialsChartingShort InterestEmployees
Logo
TPST US​

SEC Filings

Financials(60)

Expand
  • 10-QQ2ended 30 Jun 202613 Aug
  • 10-QQ1ended 31 Mar 202614 May
  • 10-KFY 2025ended 31 Dec 202530 Mar
  • 10-QQ3ended 30 Sept 20255 Nov 2025
  • 10-QQ2ended 30 Jun 202511 Aug 2025
  • 10-QQ1ended 31 Mar 202513 May 2025
  • 10-K/AFY 2024ended 31 Dec 202430 Apr 2025
  • 10-KFY 2024ended 31 Dec 202427 Mar 2025
  • 10-QQ3ended 30 Sept 202412 Nov 2024
  • 10-QQ2ended 30 Jun 20248 Aug 2024
  • 10-QQ1ended 31 Mar 20249 May 2024
  • 10-KFY 2023ended 31 Dec 202319 Mar 2024
  • 10-QQ3ended 30 Sept 20238 Nov 2023
  • 10-QQ2ended 30 Jun 202310 Aug 2023
  • 10-QQ1ended 31 Mar 202310 May 2023

Events(181)

Expand
  • 8-KSubmission of Matters to a Vote of Security Holders20 Oct
  • 8-KPRESS RELEASE, DATED OCTOBER 14, 2026, FURNISHED HEREWITH19 Oct
  • 8-KPRESS RELEASE, DATED SEPTEMBER 23, 2026, FURNISHED HEREWITH28 Sep
  • 8-KTempest Secures Exclusive Option to License Clinical-StageCD7-TargetedLentiviral In VivoCAR-TPlatform17 Sep
  • 8-KSubmission of Matters to a Vote of Security Holders16 Sep
  • 8-KEntry into a Material Definitive Agreement15 Sep
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers24 Aug
  • 8-KSubmission of Matters to a Vote of Security Holders18 Aug
  • 8-KResults of Operations and Financial Condition13 Aug
  • 8-KEntry into a Material Definitive Agreement13 Aug
  • 8-KSubmission of Matters to a Vote of Security Holders28 Jul
  • 8-KTempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, aCD7-TargetedNext-Generation In VivoCAR-T22 Jul
  • 8-KSubmission of Matters to a Vote of Security Holders22 Jun
  • 8-KTempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors4 Jun
  • 8-KEntry into a Material Definitive Agreement1 Jun

Insider Ownership(446)

Expand
  • 4Smith Nancy Freda2 Oct
  • 3Smith Nancy Freda2 Oct
  • 4Statement of changes in beneficial ownership23 Jun
  • 4Statement of changes in beneficial ownership17 Jun
  • 3Initial statement of beneficial ownership17 Jun
  • 3Initial statement of beneficial ownership8 Jun
  • 4Statement of changes in beneficial ownership8 Jun
  • 4Trojanowski Justin2 Apr
  • 4Maestas Nicholas2 Apr
  • 4Angel Matthew25 Mar
  • 4Angel Matthew6 Feb
  • 3Angel Matthew6 Feb
  • 4Simantov Ronit28 Jan
  • 4RAAB MICHAEL28 Jan
  • 4NICHOL GEOFFREY28 Jan

Beneficial Ownership(119)

Expand
  • SC 13D/ATempest Therapeutics, Inc.2 Apr
  • SC 13D/ATempest Therapeutics, Inc.25 Mar
  • SC 13DTempest Therapeutics, Inc.10 Feb
  • SC 13GTempest Therapeutics, Inc.21 Jan
  • SC 13D/ATempest Therapeutics, Inc.13 Aug 2025
  • SC 13D/ATempest Therapeutics, Inc.11 Feb 2025
  • SC 13D/ATempest Therapeutics, Inc.12 Aug 2024
  • SC 13D/ATempest Therapeutics, Inc.13 May 2024
  • SC 13G/ATempest Therapeutics, Inc.14 Feb 2024
  • SC 13G/ATempest Therapeutics, Inc.14 Feb 2024
  • SC 13G/ATempest Therapeutics, Inc.9 Feb 2024
  • SC 13D/ATempest Therapeutics, Inc.8 Feb 2024
  • SC 13D/ATempest Therapeutics, Inc.9 Nov 2023
  • SC 13G/ATempest Therapeutics, Inc.14 Feb 2023
  • SC 13GTempest Therapeutics, Inc.14 Feb 2023

Other Ownership(3)

Expand
  • 144Versant Venture Capital VI, L.P.13 Aug 2024
  • 144Versant Venture Capital VI, L.P.9 Aug 2024
  • 144Dubensky Thomas W.2 Nov 2023

Proxies(50)

Expand
  • DEFA14ACURRENT REPORT20 Oct
  • PRE 14APRELIMINARY PROXY STATEMENT16 Oct
  • DEFA14ADefinitive additional materials16 Sep
  • DEFA14ADefinitive additional materials18 Aug
  • DEFA14ADefinitive additional materials28 Jul
  • DEF 14ADefinitive proxy statement17 Jul
  • PRE 14APreliminary proxy statement7 Jul
  • DEF 14ADefinitive proxy statement8 Jun
  • PRE 14APreliminary proxy statement29 May
  • ARSAnnual report to security holders31 Dec 2025
  • DEF 14ADefinitive proxy statement31 Dec 2025
  • PRE 14APreliminary proxy statement2 Dec 2025
  • DEFA14ADefinitive additional materials19 Nov 2025
  • DEF 14ADefinitive proxy statement12 Nov 2024
  • PRE 14APreliminary proxy statement29 Oct 2024

Registrations(118)

Expand
  • 424B3PROSPECTUS2 Oct
  • S-3REGISTRATION STATEMENT25 Sep
  • 424B3Prospectus filing (Rule 424(b)(3))1 Sep
  • S-1Registration statement (general form)21 Aug
  • 424B3Prospectus filing (Rule 424(b)(3))8 Jul
  • S-3Registration statement (primary offering)26 Jun
  • 424B3Prospectus filing (Rule 424(b)(3))10 Apr
  • 424B3Prospectus filing (Rule 424(b)(3))10 Apr
  • S-3Registration statement (primary offering)1 Apr
  • S-8 POSPost-effective amendment (employee benefit plan)31 Mar
  • S-3Registration statement (primary offering)30 Mar
  • S-8Registration statement (employee benefit plan)30 Mar
  • S-1Registration statement (general form)9 Dec 2025
  • 424B5Prospectus filing (Rule 424(b)(5))25 Nov 2025
  • 424B5Prospectus filing (Rule 424(b)(5))12 Jun 2025

Filing Review Correspondence(15)

Expand
  • CORRESPFiling review correspondence27 Aug
  • CORRESPFiling review correspondence2 Jul
  • CORRESPFiling review correspondence8 Apr
  • CORRESPFiling review correspondence1 Apr
  • CORRESPFiling review correspondence30 Dec 2025
  • CORRESPFiling review correspondence23 Dec 2025
  • CORRESPFiling review correspondence24 Jan 2025
  • CORRESPFiling review correspondence24 May 2022
  • CORRESPFiling review correspondence22 Jul 2021
  • CORRESPFiling review correspondence7 May 2021
  • CORRESPFiling review correspondence16 Apr 2019
  • CORRESPFiling review correspondence3 Dec 2018
  • CORRESPFiling review correspondence16 Nov 2018
  • CORRESPFiling review correspondence1 Nov 2018
  • CORRESPFiling review correspondence4 May 2016

SEC Orders And Notices(29)

Expand
  • EFFECTNotice of effectiveness2 Oct
  • EFFECTNotice of effectiveness1 Sep
  • EFFECTNotice of effectiveness8 Jul
  • EFFECTNotice of effectiveness10 Apr
  • EFFECTNotice of effectiveness6 Apr
  • EFFECTNotice of effectiveness2 Jan
  • EFFECTNotice of effectiveness27 Jan 2025
  • EFFECTNotice of effectiveness27 May 2022
  • EFFECTNotice of effectiveness23 Jul 2021
  • EFFECTNotice of effectiveness11 May 2021
  • EFFECTNotice of effectiveness18 Apr 2019
  • EFFECTNotice of effectiveness6 Dec 2018
  • CT ORDERConfidential treatment order7 Nov 2018
  • EFFECTNotice of effectiveness5 Nov 2018
  • CT ORDERConfidential treatment order15 May 2018

Exempt Offerings(10)

Expand
  • DRule 506(b) provides a "safer harbor" for a private offering13 Oct
  • DRule 506(b) provides a "safer harbor" for a private offering22 Jun
  • DRule 506(b) provides a "safer harbor" for a private offering3 Apr
  • D06b11 May 2022
  • DNotice of exempt offering of securities (Reg D)28 Mar 2013
  • D/ANotice of exempt offering of securities (Reg D, amendment)14 Aug 2012
  • D/ANotice of exempt offering of securities (Reg D, amendment)3 Aug 2012
  • D/ANotice of exempt offering of securities (Reg D, amendment)20 Jul 2012
  • DNotice of exempt offering of securities (Reg D)5 Jul 2012
  • DNotice of exempt offering of securities (Reg D)9 Apr 2012

Other(1)

Expand
  • CERTNASAUTO-GENERATED PAPER DOCUMENT29 Apr 2013